Cargando…

Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study

Advanced high-grade serous ovarian carcinoma is a serious malignant neoplasm with a late diagnosis and high mortality rate. Even when treated with standard therapy, such as surgery followed by carboplatin and paclitaxel chemotherapy, the prognosis remains unfavorable. Immunotherapy is a treatment al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dergham, Ana Paula, Vaz de Paula, Caroline Busatta, Nagashima, Seigo, Olandoski, Márcia, de Noronha, Lucia, Sotomaior, Vanessa Santos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381449/ https://www.ncbi.nlm.nih.gov/pubmed/37511658 http://dx.doi.org/10.3390/jpm13071045

Ejemplares similares

Covid-19 cytokine storm in pulmonary tissue: Anatomopathological and immunohistochemical findings
por: Ribeiro dos Santos Miggiolaro, Anna Flavia, et al.
Publicado: (2020)

COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis
por: Vaz de Paula, Caroline Busatta, et al.
Publicado: (2021)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
por: Oliveira, André F., et al.
Publicado: (2019)

The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses
por: Cui, Guanglin
Publicado: (2021)

EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes
por: De Rosa, Simona, et al.
Publicado: (2018)

Role of the NF-kB/parkin/vegfr-1 pathway associated with hypoxic-ischemic insult in germinal matrix samples of newborn infants
por: Ghirelli, Eliane Amaral, et al.
Publicado: (2023)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
por: Martin de la Fuente, Laura, et al.
Publicado: (2020)

Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression
por: Li, Na, et al.
Publicado: (2022)

Correlation of PD-L1 immunohistochemical expression with microsatellite instability and p53 status in endometrial carcinoma
por: Arafa, Mohammad, et al.
Publicado: (2022)

Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis
por: Motta Junior, Jarbas da Silva, et al.
Publicado: (2020)

Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis
por: Choi, Jina, et al.
Publicado: (2023)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

Polymorphisms in TPT1 Pathways in Pediatric Astrocytomas
por: Morais de Castro, Eduardo, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
por: Maekawa, Naoya, et al.
Publicado: (2016)

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies
por: Gravelle, Pauline, et al.
Publicado: (2017)

PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer
por: Russo, Giorgio Ivan, et al.
Publicado: (2022)

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2017)

Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
por: Liu, Ping, et al.
Publicado: (2022)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
por: Du, YunYi, et al.
Publicado: (2022)

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2023)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Sobral, Patrícia S., et al.
Publicado: (2023)

PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance
por: Zhang, Tao, et al.
Publicado: (2021)

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
por: Scognamiglio, Giosuè, et al.
Publicado: (2016)

Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer
por: Baş, Yılmaz, et al.
Publicado: (2020)

The Pathogenesis of COVID-19 Myocardial Injury: An Immunohistochemical Study of Postmortem Biopsies
por: Hartmann, Camila, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Role of Genetic Polymorphism Present in Macrophage Activation Syndrome Pathway in Post Mortem Biopsies of Patients with COVID-19
por: Zanchettin, Aline Cristina, et al.
Publicado: (2022)

B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy
por: Zhang, Chenzhi, et al.
Publicado: (2022)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
por: Fujisawa, Takuo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_daejsuum698qn7nti7g6ui05pd